Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fosun Pharma
Biotech
Fosun rises again, beaming up 3rd biotech deal in 3 weeks
Fosun has penned its third inflammatory disease pact in three weeks, plucking up China rights to an investigational drug from Accro Bioscience.
Gabrielle Masson
Aug 29, 2025 10:05am
Sitala seals $670M deal for Fosun immune disease drug
Aug 26, 2025 2:44pm
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
Fosun, Treehill join forces to invest in drugs angling for US
Nov 20, 2023 6:30am
China’s Wanbang expands partnership with Canadian biotech Sirona
Nov 23, 2022 11:20am
Lilly gives up on $40M BCL-2 buy as part of latest pipeline cull
Nov 1, 2022 9:42am
